Montpellier, France – NFL Biosciences, a biopharmaceutical company specializing in botanical drugs for addiction treatment, has received a significant financial boost. Bpifrance has granted the company a €500,000 loan to support the preparation of its Phase 2 clinical trial application for NFL-102, a novel drug candidate targeting nicotine addiction. The loan, announced on March 11, 2026, includes a 36-month repayment deferral, providing NFL Biosciences with crucial financial flexibility.
The funding arrives at a pivotal moment for the company, as it prepares to submit its application for the next stage of clinical trials. NFL-102 has shown promising results in preclinical studies, specifically in a mouse model conducted by the French Alternative Energies and Atomic Energy Commission (CEA). These studies indicate a unique mechanism of action in addressing the underlying causes of nicotine dependence.
Novel Approach to Nicotine Addiction
Nicotine addiction remains a major global health challenge, impacting millions worldwide. Current treatments often have limited efficacy or significant side effects. NFL Biosciences is attempting to address this gap with a botanical approach, leveraging the potential of natural compounds to modulate brain activity related to addiction. The company’s research focuses on normalizing CREB activity, a transcription factor recognized as a key regulator in tobacco addiction. Understanding CREB’s role is crucial, as it influences the brain’s reward pathways and contributes to the compulsive behaviors associated with nicotine employ.
The preclinical study conducted by the CEA highlighted NFL-102’s ability to influence these pathways. While the research is still in its early stages, the findings suggest a potential for a new therapeutic strategy. It’s important to note that preclinical results do not always translate to success in human clinical trials, but they provide a strong foundation for further investigation.
Bpifrance’s Continued Support
This isn’t the first time Bpifrance has invested in NFL Biosciences, signaling confidence in the company’s research and development efforts. The renewed financial support is described as “non-dilutive,” meaning it doesn’t require the company to issue additional shares, preserving existing ownership structure. This is particularly valuable for smaller biopharmaceutical companies like NFL Biosciences, allowing them to maintain control while securing necessary funding.
Bruno Lafont, Chief Executive Officer and Co-founder of NFL Biosciences, expressed gratitude for Bpifrance’s continued support. “We warmly thank Bpifrance for its renewed confidence and continued support for the development of NFL Biosciences. This new loan represents additional non-dilutive support for the Company,” Lafont said in a press release. The CEO’s statement underscores the importance of this funding in enabling the company to move forward with its clinical trial preparations.
NFL Biosciences: A Focus on Botanical Drugs
Based in the Montpellier region of France, NFL Biosciences is dedicated to developing botanical drug candidates for a range of addictions. The company’s ambition is to provide safer and more effective therapeutic solutions, particularly for populations in low- and middle-income countries. This commitment to accessibility reflects a broader trend in pharmaceutical research, aiming to address global health needs beyond developed markets.
NFL-101 and NFL-102 are both standardized tobacco leaf extracts protected by four patent families, demonstrating the company’s commitment to intellectual property and innovation. The patent protection is vital for securing the company’s future and attracting further investment.
What’s Next for NFL-102?
The immediate focus for NFL Biosciences is preparing the submission for the Phase 2 clinical trial application, expected in mid-2026. This phase will involve testing the drug candidate on a larger group of human participants to assess its safety and efficacy. Successful completion of Phase 2 trials is a critical step towards potential regulatory approval and eventual market availability.
The company’s website, www.nflbiosciences.com, provides further information about its research and development pipeline. Investors and those interested in the company’s progress can discover updates on its Euronext Growth Paris listing (FR0014003XT0 – ALNFL). The next major milestone will be the announcement of the Phase 2 trial application submission, which will be closely watched by the biopharmaceutical industry and those affected by nicotine addiction.
Keep reading
